Imugene Limited (ASX: IMU) - Share Price

Current share price for IMU : $0.105 0.014 (15.38%)⁺

Imugene Limited (IMU), an ASX-listed company, is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. The Company's unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

IMU General Information ⁺

ASX Code	IMU
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	43
IMU Share Price	$0.105
Day High	$0.105
Day Low	$0.092
Last Close	$0.091
IMU Share Price Movement	$0.01 ( 15.38% )

Prices as at 16:40, 15 Jun 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Imugene Limited (IMU) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Imugene Limited (IMU) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Imugene Limited (IMU) price-sensitive announcements

IMU - Azer-cel Granted FDA Fast Track Designation for CLL and MZL

Imugene Limited announced that the US FDA has granted Fast Track Designation to their azer

Imugene Limited (IMU)
9 Jun 2026 | 10:50 AM

IMU - First Patient in BTKi Combination Cohort of azer-cel study

Imugene Limited has announced the administration of the first dose to a patient in the Bru

Imugene Limited (IMU)
28 May 2026 | 9:41 AM

IMU - Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract

Imugene Limited has released promising data on Azer-cel from a Phase 1b study involving a

Imugene Limited (IMU)
22 May 2026 | 9:27 AM

IMU - Quarterly Activities/Appendix 4C Cash Flow Report

Imugene Limited, a clinical-stage immuno-oncology company, provided an update for the quar

Imugene Limited (IMU)
30 Apr 2026 | 11:29 AM

Imugene Limited (IMU) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Imugene Limited (IMU) ORDINARY FULLY PAID	Health Care	$44	Azer-cel Granted FDA Fast Track Designation for CLL and MZL	9 Jun 2026 10:50AM	$0.091	$0.105	risen by 16.02%
Imugene Limited (IMU) ORDINARY FULLY PAID	Health Care	$44	Notification regarding unquoted securities - IMU	2 Jun 2026 5:57PM	$0.105	$0.105	fallen by 0%
Imugene Limited (IMU) ORDINARY FULLY PAID	Health Care	$44	azer-cel CAR-T naive data presented at ASCO Annual Meeting	1 Jun 2026 8:33AM	$0.115	$0.105	fallen by 8.70%
Imugene Limited (IMU) ORDINARY FULLY PAID	Health Care	$44	First Patient in BTKi Combination Cohort of azer-cel study	28 May 2026 9:41AM	$0.110	$0.105	fallen by 4.55%
Imugene Limited (IMU) ORDINARY FULLY PAID	Health Care	$44	Appointment of 2 non-Executive Directors	26 May 2026 9:47AM	$0.110	$0.105	fallen by 4.55%
Imugene Limited (IMU) ORDINARY FULLY PAID	Health Care	$44	Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract	22 May 2026 9:27AM	$0.096	$0.105	risen by 9.37%

IMU Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$69.02	-$31.60	-47.50%	0.00%	0.0%
2024A	-$125.37	-$60.10	113.20%	0.00%	0.0%
2023A	-$52.40	-$28.20	140.20%	0.00%	0.0%

IMU Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
CSL Limited (CSL)	$51,354M	0.1108	-0.1365	0.0438	11.4983	13.3154	12.7567	4.16%	3.34%	3.47%
Clinuvel Pharmaceuticals Limited (CUV)	$446M	0.0287	0.0233	0.0942	12.3259	12.0457	11.0088	0.56%	0.82%	1.32%
Imugene Limited (IMU)	$38M	-0.4751	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,550M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$4,571M	-1.3893	0.0000	-0.1316	0.0000	253.1955	291.5584	0.00%	0.00%	0.00%

IMU Directors

Name	Position	Start Date
Ms Leslie (Mi Ok) Chong	Chief Executive Officer, Managing Director	28 Mar 2018
Mr Paul Alex Hopper	Executive Chairman, Executive Director	31 Oct 2012
Mr Michael John Kotsanis	Non-Executive Director	26 May 2026
Dr Lesley Russell	Non-Executive Director	23 Apr 2019
Dr Charmaine Hilary Gittleson	Non-Executive Director	26 May 2026
Dr Jakob Dupont	Non-Executive Director	7 Sep 2022
Ms Kim Drapkin	Non-Executive Director	21 Jun 2023

Imugene Limited (IMU) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
14 May 2026	CHONG, Leslie (Mi Ok)	Buy	Direct Shares	355,164	$0.103	$36,404.310
14 May 2026	HOPPER, Paul	Buy	Direct Shares	180,000	$0.104	$18,648.000
11 May 2026	CHONG, Leslie (Mi Ok)	Buy	Direct Shares	230,285	$0.108	$24,755.638

See all changes in directors' interest & trades for Imugene Limited (IMU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMU Management

Name	Position
Darren Keamy	Chief Financial Officer
Darren Keamy	Chief Financial Officer,Company Secretary
John Byon	Chief Medical Officer
Bradley Glover	Chief Operating Officer

IMU Calendar of Events

Date	Event
24 February 2027	Report (Interim)
25 August 2026	Report (Annual)
25 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us